Member Info for Sillbill

even I bought this after reading the IC article and questor, should be ok for long term, it may go down further in the near term.

following foot steps of Thomas cook

passed 188 threshold, next is 212

Oops!

Passed the resistance level of 158, next is 183. Will it happen today? I am still holding.

Results are impressive. Also Indian contract should help them. India has recently improved trading ties wit SA. I am surprised that SP hasn't shot up. I think fund managers are yet to digest the results or have negative approach with SA mining companies. If the price doesn't take off in near term, it may be taken over.

Good news. Furnaces operating at full load. Should hear more on 24th Jan.

More buys today ? It appears the sp should take off. Any one has views on this buy.

Should have projected next years projections as the furnace is working fully. This would have offset 2nd quarter reduction of 15%. Market doesn't like uncertainty. Luckily the price is holding on.

we should hear news about flutiform soon and hopefully see this share price in 3 digit figure.

CEO says that shareholders may get little or on no value. So we may get 1p like cattle

Take over looks likely , http://mobile.reuters.com/shortArticle/Deals/idUS109648+02-Mar-2011+HUG20110302

definite upward trend, shuld hear some good news

slowly creeping up, hopefully should hear some takeover news soon

there was an corporate actions alert on selftrade , ORA has increased their holdings http://www.selftrade.co.uk/news-information/news.php?fullview=1&idNews=9536110&submit=

I don't see any change in SP until AGM

http://www.reuters.com/article/2011/02/08/southern-cross-idUSLDE7170FA20110208

Not bad, some relief as NHS hospitals are sending pts to SCHE, also self funding clients gone up

The company mainly lease nursing homes, they still have to higher rent to the owners. The CEO did comment in Telegraph that company may go under. They are negotiating with owners to reduce the rent. The councils are cutting their budget. It is catch 22.

SkyePharma's investment case depends on the EU approval of Flutiform - which is possible by Q3 - and centres on the product's subsequent achievement of our targeted 5% penetration of the European ICS/LABA market. In this scenario, we estimate the equity to have a fair value of 374p per share. However, the upside has to be considered alongside the fact that SkyePharma's convertible bonds will have to be refinanced by 2013, an event that may have a dilutive effect on equity.